We also identified that NMe-Gly11 substitution can improve the tumor uptake and tumor-to-organ uptake ratios of 68Ga-labeled GRPR antagonists derived from the [Leu13(ψ)Thz14]Bombesin(6–14) pharmacophore [20,23]. The gene discussed is GRPR; the disease is neoplasm.